Skip to main content

AWIQLI (Novo Nordisk Pharmaceuticals Pty Ltd)

Product name
AWIQLI
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
insulin icodec
Registration type
NCE/ NBE
Indication

Treatment of Type 2 Diabetes in adults.

Treatment of Type 1 Diabetes in adults, in conjunction with a bolus insulin, where daily basal insulin injections are not suitable.

Help us improve the Therapeutic Goods Administration site